Fludarabine in the Treatment of Lymphoproliferative Malignancies
- 1 January 1993
- journal article
- review article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 11 (3) , 314-318
- https://doi.org/10.3109/07357909309024858
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.Journal of Clinical Oncology, 1991
- Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.Journal of Clinical Oncology, 1991
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working groupAmerican Journal of Hematology, 1988
- Pulmonary toxicity associated with fludarabine monophosphateInvestigational New Drugs, 1987
- Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.Journal of Clinical Oncology, 1986
- Incorporation of 9-β-d-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNABiochemical Pharmacology, 1986
- Low-dose deoxycoformycin in lymphoid malignancy.Journal of Clinical Oncology, 1985
- The inhibition of ultraviolet radiation-induced DNA repair in human diploid fibroblasts by arabinofuranosyl nucleosidesChemico-Biological Interactions, 1984
- Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemiaBlood, 1977
- Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemiaCancer, 1973